HCWB
HCW Biologics Inc.
Price Chart
Latest Quote
$1.09
+0.01 (+0.94%)
Current Price
| Previous Close | $1.08 |
| Open | $1.05 |
| Day High | $1.12 |
| Day Low | $1.03 |
| Volume | 157,063 |
Stock Information
| Shares Outstanding | 7.16M |
| Total Debt | $6.58M |
| Cash Equivalents | $1.23M |
| Revenue | $6.59M |
| Net Income | $-18.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.81M |
| EPS (TTM) | $-8.29 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.62M |
| Sales | $6.59M |
| Income | $-18.12M |
| Book/sh | $0.86 |
| Cash/sh | $0.17 |
| Employees | 35 |
Financial Ratios
| Quick Ratio | 0.07 |
| Current Ratio | 0.09 |
| Debt/Eq | 114.14 |
Returns & Margins
| ROA | -15.06% |
| Gross Margin | 99.23% |
| Operating Margin | 49.45% |
| Profit Margin | -34.74% |
Ownership
| Insider Ownership | 12.37% |
| Institutional Ownership | 11.50% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.98 |
| P/S | 1.18 |
| P/B | 1.27 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $1.46 |
| SMA50 | $1.04 |
| SMA200 | $1.79 |
| RSI | 21.37 |
| ATR | 0.1689 |
| Shares Float | 5.85M |
| Short Float | 6.35% |
| Short Ratio | 0.01 |
| Volatility | 2.21 |
| Rel Volume | 0.10 |
Performance History
| Week | -4.37% |
| Month | -62.28% |
| Quarter | +156.52% |
| 6 Months | -30.56% |
| YTD | -2.66% |
| Year | -76.66% |
| 3 Years | -98.71% |
| 10 Years | -99.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.09 | 157,063 |
| 2026-06-23 | $1.08 | 289,000 |
| 2026-06-22 | $1.16 | 4,492,200 |
| 2026-06-18 | $1.09 | 939,500 |
| 2026-06-17 | $1.10 | 546,900 |
| 2026-06-16 | $1.14 | 4,311,300 |
| 2026-06-15 | $1.22 | 346,600 |
| 2026-06-12 | $1.28 | 530,800 |
| 2026-06-11 | $1.32 | 1,304,100 |
| 2026-06-10 | $1.21 | 905,200 |
| 2026-06-09 | $1.18 | 886,400 |
| 2026-06-08 | $1.45 | 654,000 |
| 2026-06-05 | $1.63 | 793,700 |
| 2026-06-04 | $1.63 | 801,700 |
| 2026-06-03 | $1.68 | 1,262,100 |
| 2026-06-02 | $1.79 | 1,730,600 |
| 2026-06-01 | $2.07 | 3,484,500 |
| 2026-05-29 | $1.98 | 2,540,900 |
| 2026-05-28 | $2.09 | 3,449,400 |
| 2026-05-27 | $1.94 | 3,418,700 |
| 2026-05-26 | $2.62 | 3,026,000 |
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
đ° Latest News
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
24/7 Wall St. âĸ 2026-05-18T14:35:31Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-03-16T14:30:26ZWall Street Set to Open Little Changed Friday Ahead of Consumer Sentiment Report
MT Newswires âĸ 2025-09-12T13:21:29ZConsumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session
MT Newswires âĸ 2025-09-12T12:03:49ZHCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024)
Simply Wall St. âĸ 2025-08-16T12:18:46Z
Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m
Simply Wall St. âĸ 2025-07-02T14:27:37Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $43,386 | $677,407 | $1,413,013 | $3,756,316 |
| Cost Of Revenue | $43,386 | $1,607,389 | $2,281,434 | $4,135,712 |
| Total Revenue | $54,232 | $2,566,792 | $2,841,794 | $6,722,090 |
| Operating Revenue | $54,232 | $2,566,792 | $2,841,794 | $6,722,090 |
| Expenses | ||||
| Interest Expense | $1,250,273 | $1,181,588 | $283,042 | $126,660 |
| Total Expenses | $11,311,520 | $30,196,008 | $28,558,954 | $21,800,868 |
| Rent Expense Supplemental | $191,598 | $205,511 | $156,807 | $132,739 |
| Other Income Expense | $4,547,852 | $-1,213,010 | $1,005,925 | $304,735 |
| Other Non Operating Income Expenses | $6,585,248 | $-1,213,010 | $1,005,925 | $304,735 |
| Net Non Operating Interest Income Expense | $-1,250,273 | $-1,181,588 | $-283,042 | $-126,660 |
| Interest Expense Non Operating | $1,250,273 | $1,181,588 | $283,042 | $126,660 |
| Operating Expense | $11,268,134 | $28,588,619 | $26,277,520 | $17,665,156 |
| General And Administrative Expense | $5,588,245 | $21,945,218 | $13,084,441 | $7,988,333 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Interest Income | $-1,250,273 | $-1,181,588 | $-283,042 | $-126,660 |
| Normalized Income | $-5,922,313 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Income From Continuing And Discontinued Operation | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Total Operating Income As Reported | $-13,162,510 | $-29,456,520 | $-25,717,160 | $-15,078,778 |
| Net Income Common Stockholders | $-22,298,702 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Income | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Income Including Noncontrolling Interests | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Income Continuous Operations | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Pretax Income | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Special Income Charges | $-1,500,000 | $0 | $-6,571,689 | - |
| Operating Income | $-11,257,288 | $-27,629,216 | $-25,717,160 | $-15,078,778 |
| Depreciation Amortization Depletion Income Statement | $237,005 | $254,407 | $266,763 | $338,458 |
| Depreciation And Amortization In Income Statement | $237,005 | $254,407 | $266,763 | $338,458 |
| Depreciation Income Statement | $237,005 | $254,407 | $266,763 | $338,458 |
| Gross Profit | $10,846 | $959,403 | $560,360 | $2,586,378 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-10.63 | $-30.80 | $-28.00 | $-16.80 |
| Basic EPS | $-10.63 | $-30.80 | $-28.00 | $-16.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,630,269 | $-27,657,837 | $-23,576,051 | $-14,056,189 |
| Total Unusual Items | $-2,037,396 | $0 | $-6,571,689 | - |
| Total Unusual Items Excluding Goodwill | $-2,037,396 | $0 | $-6,571,689 | - |
| Reconciled Depreciation | $1,041,771 | $1,184,389 | $1,135,184 | $717,854 |
| EBITDA (Bullshit earnings) | $-5,667,665 | $-27,657,837 | $-23,576,051 | $-14,056,189 |
| EBIT | $-6,709,436 | $-28,842,226 | $-24,711,235 | $-14,774,043 |
| Diluted Average Shares | $2,097,701 | $969,825 | $898,236 | $895,556 |
| Basic Average Shares | $2,097,701 | $969,825 | $898,236 | $895,556 |
| Diluted NI Availto Com Stockholders | $-22,298,702 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Otherunder Preferred Stock Dividend | $14,338,993 | $0 | - | - |
| Impairment Of Capital Assets | $1,500,000 | $0 | - | - |
| Gain On Sale Of Security | $-537,396 | - | - | - |
| Research And Development | $5,442,884 | $6,388,994 | $7,676,316 | $9,338,365 |
| Selling General And Administration | $5,588,245 | $21,945,218 | $13,084,441 | $7,988,333 |
| Other Gand A | $2,611,894 | $19,175,771 | $9,710,774 | $4,476,330 |
| Rent And Landing Fees | $191,598 | $205,511 | $156,807 | $132,739 |
| Salaries And Wages | $2,784,753 | $2,563,936 | $3,216,860 | $3,379,264 |
| Other Special Charges | - | $15,910,480 | $6,571,689 | - |
| Provision For Doubtful Accounts | - | $1,300,000 | $5,250,000 | $0 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,764,769 | $-6,770,172 | $13,461,717 | $37,428,506 |
| Total Assets | $24,520,013 | $30,236,578 | $28,513,660 | $46,809,155 |
| Total Non Current Assets | $22,235,654 | $24,538,096 | $22,109,473 | $12,738,236 |
| Other Non Current Assets | $28,476 | $28,476 | $56,538 | $333,875 |
| Current Assets | $2,284,359 | $5,698,482 | $6,404,187 | $34,070,919 |
| Other Current Assets | $77,564 | $113,528 | $230,916 | $196,015 |
| Prepaid Assets | $222,156 | $328,181 | $1,042,413 | $1,394,923 |
| Receivables | $32,175 | $582,201 | $1,535,757 | $417,695 |
| Accounts Receivable | $32,175 | $582,201 | $1,535,757 | $417,695 |
| Cash Cash Equivalents And Short Term Investments | $1,952,464 | $4,674,572 | $3,595,101 | $32,062,286 |
| Cash And Cash Equivalents | $1,952,464 | $4,674,572 | $3,595,101 | $22,326,356 |
| Cash Equivalents | - | $3,748,325 | $1,626,129 | $19,458,020 |
| Cash Financial | - | $926,247 | $1,968,972 | $2,868,336 |
| Debt | ||||
| Net Debt | $4,856,751 | $9,017,977 | $2,709,217 | - |
| Total Debt | $6,809,215 | $13,692,549 | $6,304,318 | $6,409,893 |
| Current Debt And Capital Lease Obligation | $6,809,215 | $6,314,684 | - | - |
| Current Debt | $6,809,215 | $6,314,684 | - | - |
| Long Term Debt And Capital Lease Obligation | - | $7,377,865 | $6,304,318 | $6,409,893 |
| Long Term Debt | - | $7,377,865 | $6,304,318 | $6,409,893 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,755,244 | $37,006,750 | $15,051,943 | $9,380,649 |
| Total Non Current Liabilities Net Minority Interest | $692,531 | $7,377,865 | $6,304,318 | $6,424,168 |
| Other Non Current Liabilities | $692,531 | - | - | $14,275 |
| Current Liabilities | $21,062,713 | $29,628,885 | $8,747,625 | $2,956,481 |
| Payables And Accrued Expenses | $14,253,498 | $23,314,201 | $8,747,625 | $2,956,481 |
| Payables | $13,143,394 | $22,332,261 | $6,167,223 | $1,226,156 |
| Accounts Payable | $13,143,394 | $22,332,261 | $6,167,223 | $1,226,156 |
| Equity | ||||
| Common Stock Equity | $2,764,769 | $-6,770,172 | $13,461,717 | $37,428,506 |
| Total Equity Gross Minority Interest | $2,764,769 | $-6,770,172 | $13,461,717 | $37,428,506 |
| Stockholders Equity | $2,764,769 | $-6,770,172 | $13,461,717 | $37,428,506 |
| Retained Earnings | $-108,515,846 | $-100,556,137 | $-70,532,323 | $-45,538,046 |
| Other | ||||
| Ordinary Shares Number | $3,279,812 | $1,113,532 | $900,627 | $896,911 |
| Share Issued | $3,279,812 | $1,113,532 | $900,627 | $896,911 |
| Tangible Book Value | $2,764,769 | $-6,770,172 | $13,461,717 | $37,428,506 |
| Invested Capital | $9,573,984 | $6,922,377 | $19,766,035 | $43,838,399 |
| Working Capital | $-18,778,354 | $-23,930,403 | $-2,343,438 | $31,114,438 |
| Total Capitalization | $2,764,769 | $607,693 | $19,766,035 | $43,838,399 |
| Additional Paid In Capital | $111,280,287 | $93,785,854 | $83,990,437 | $82,962,964 |
| Capital Stock | $328 | $111 | $3,603 | $3,588 |
| Common Stock | $328 | $111 | $3,603 | $3,588 |
| Line Of Credit | $6,809,215 | $6,314,684 | $0 | - |
| Current Accrued Expenses | $1,110,104 | $981,940 | $2,580,402 | $1,730,325 |
| Investments And Advances | $1,326,329 | $1,599,751 | $1,599,751 | $1,599,751 |
| Net PPE | $20,880,849 | $22,909,869 | $20,453,184 | $10,804,610 |
| Accumulated Depreciation | $-4,183,478 | $-3,676,458 | $-3,031,841 | $-2,237,222 |
| Gross PPE | $25,064,327 | $26,586,327 | $23,485,025 | $13,041,832 |
| Leases | $354,276 | $354,276 | $354,276 | $349,976 |
| Construction In Progress | $12,023,161 | $13,545,161 | $10,443,859 | $52,414 |
| Other Properties | $3,913,868 | $3,913,868 | $3,913,868 | $3,882,384 |
| Machinery Furniture Equipment | $517,414 | $517,414 | $517,414 | $501,450 |
| Buildings And Improvements | $6,105,570 | $6,105,570 | $6,105,570 | $6,105,570 |
| Land And Improvements | $2,150,038 | $2,150,038 | $2,150,038 | $2,150,038 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Other Short Term Investments | - | - | $0 | $9,735,930 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,391,617 | $-14,489,045 | $-28,716,721 | $-20,661,238 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,391,617 | $-14,227,428 | $-22,514,121 | $-10,386,110 |
| Cash Flow From Continuing Operating Activities | $-13,391,617 | $-14,227,428 | $-22,514,121 | $-10,386,110 |
| Operating Gains Losses | $-5,197,072 | - | $-15,625 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-261,617 | $3,797,400 | $14,708,392 |
| Cash Flow From Continuing Investing Activities | $0 | $-261,617 | $3,797,400 | $14,708,392 |
| Capital Expenditure | - | $-261,617 | $-6,202,600 | $-10,275,128 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,034,017 | $6,462,834 | $23,739 | $15,778 |
| Financing Cash Flow | $10,669,509 | $15,568,516 | $-14,534 | $6,273,397 |
| Cash Flow From Continuing Financing Activities | $10,669,509 | $15,568,516 | $-14,534 | $6,273,397 |
| Net Other Financing Charges | $-1,209,779 | $-638,045 | - | $-190,547 |
| Net Common Stock Issuance | $8,034,017 | $6,462,834 | $23,739 | $15,778 |
| Common Stock Issuance | $8,034,017 | $6,462,834 | $23,739 | $15,778 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-127,623 | $-119,398 | $-38,273 | $0 |
| Issuance Of Debt | $150,000 | $6,905,000 | $0 | $6,448,166 |
| Interest Paid Supplemental Data | $283,042 | $569,770 | $283,042 | $126,660 |
| End Cash Position | $1,952,464 | $4,674,572 | $3,595,101 | $22,326,356 |
| Beginning Cash Position | $4,674,572 | $3,595,101 | $22,326,356 | $11,730,677 |
| Changes In Cash | $-2,722,108 | $1,079,471 | $-18,731,255 | $10,595,679 |
| Proceeds From Stock Option Exercised | $3,822,894 | $2,958,125 | $0 | - |
| Net Issuance Payments Of Debt | $22,377 | $6,785,602 | $-38,273 | $6,448,166 |
| Net Long Term Debt Issuance | $22,377 | $6,785,602 | $-38,273 | $6,448,166 |
| Long Term Debt Payments | $-127,623 | $-119,398 | $-38,273 | $0 |
| Long Term Debt Issuance | $150,000 | $6,905,000 | $0 | $6,448,166 |
| Net PPE Purchase And Sale | $0 | $-261,617 | $-6,202,600 | $-10,275,128 |
| Purchase Of PPE | $0 | $-261,617 | $-6,202,600 | $-10,275,128 |
| Change In Working Capital | $-2,781,691 | $13,603,404 | $-4,643,036 | $2,488,089 |
| Change In Other Current Liabilities | $0 | $-56,541 | $-326,742 | $-128,246 |
| Change In Payables And Accrued Expense | $-3,473,706 | $11,874,767 | $1,619,357 | $418,208 |
| Change In Payable | $-3,473,706 | $11,874,767 | $1,619,357 | $418,208 |
| Change In Account Payable | $-3,473,706 | $11,874,767 | $1,619,357 | $418,208 |
| Change In Prepaid Assets | $141,989 | $831,622 | $-4,817,590 | $2,482,822 |
| Change In Receivables | $550,026 | $953,556 | $-1,118,061 | $-284,695 |
| Changes In Account Receivables | $550,026 | $953,556 | $-1,118,061 | $-284,695 |
| Other Non Cash Items | $-1,036,961 | $-418 | $-1,671 | $2,089 |
| Stock Based Compensation | $768,623 | $1,009,011 | $1,003,749 | $1,120,191 |
| Unrealized Gain Loss On Investment Securities | $273,422 | $0 | $-248,445 | $186,370 |
| Asset Impairment Charge | $1,500,000 | $0 | - | - |
| Depreciation Amortization Depletion | $1,041,771 | $1,184,389 | $1,135,184 | $717,854 |
| Depreciation And Amortization | $1,041,771 | $1,184,389 | $1,135,184 | $717,854 |
| Gain Loss On Investment Securities | $263,974 | - | $-15,625 | - |
| Net Income From Continuing Operations | $-7,959,709 | $-30,023,814 | $-24,994,277 | $-14,900,703 |
| Net Investment Purchase And Sale | - | $0 | $10,000,000 | $24,983,520 |
| Sale Of Investment | - | $0 | $10,000,000 | $24,983,520 |
| Provisionand Write Offof Assets | - | $0 | $5,250,000 | $0 |
| Purchase Of Investment | - | - | - | $0 |
Fetched: 2026-06-18